How does IQVIA make money?

IQVIA HOLDINGS INC. – Business Breakdown

The Essentials

IQVIA Holdings Inc. is a global healthcare services and outsourcing platform serving life sciences and healthcare clients through three distinct operating segments: Technology & Analytics Solutions (TAS), Research & Development Solutions (RDS), and Contract Sales & Medical Solutions (CSMS). The business is structurally important within the pharmaceutical and broader healthcare ecosystem because it combines clinical research execution, commercial intelligence, and healthcare data analytics at scale.

The company’s operating footprint is broad and deeply embedded: it serves pharmaceutical, biotechnology, device, diagnostic, and consumer health customers across the Americas, Europe, Africa, and Asia-Pacific, with 304 offices and laboratories in 87 countries. Its economic model is underpinned by a large proprietary data estate, extensive client relationships, and a meaningful backlog in R&D services, which together support revenue visibility and strategic relevance.

Business Model & Revenue Drivers

IQVIA generates economic value through three primary engines:

• Technology & Analytics Solutions (TAS) — 40.4% of FY 2025 revenue

  • Delivers cloud-based applications, implementation services, real-world evidence solutions, and advanced analytics.
  • Supports commercial decision-making through measurement of sales, prescribing, and promotional activity at granular geographic and prescriber levels.
  • The segment is materially supported by proprietary data assets, including 1.2+ billion longitudinal non-identified patient records, ~68 petabytes of proprietary data, and 1+ million data feeds.
  • FY 2025 revenue was $6.6 billion, up 7.6%, with segment profit of $1.54 billion and a 23.3% margin.

• Research & Development Solutions (RDS) — 54.7% of FY 2025 revenue

  • Provides project management, clinical monitoring, trial design, patient/site-centric solutions, and a broad laboratory offering including central lab, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker services.
  • This is the company’s largest revenue contributor and the core driver of backlog visibility.
  • Contracted backlog stood at $32.7 billion at year-end 2025, with approximately $8.1 billion expected to convert into revenue over the next 12 months.
  • FY 2025 revenue was $8.922 billion, up 4.3%, with segment profit of $1.9 billion and a 21.3% margin.

• Contract Sales & Medical Solutions (CSMS) — 4.8% of FY 2025 revenue

  • Provides healthcare provider engagement, contract sales, patient engagement, scientific strategy, and medical affairs services.
  • Plays a supporting role in commercialization and launch execution, and the profile states it supported ~80% of new drug launches globally.
  • FY 2025 revenue was $788 million, up 9.7%, with segment profit of $100 million and a 12.7% margin.

Across the group, FY 2025 revenues reached $16.31 billion, with adjusted EBITDA of $3.788 billion and free cash flow of $2.1 billion, indicating a business that converts earnings into cash at a high rate.

Strategic Edge & Market Positioning

IQVIA’s competitive position appears to rest on a combination of structural and execution-based advantages.

Economic Moat

• Data and network effects: The strongest structural advantage is its proprietary healthcare data ecosystem. The company cites one of the largest healthcare information collections in the world, spanning sales, prescription, promotional, claims, electronic medical records, and genomics data. The scale of this dataset, together with 150,000+ data suppliers and 90% coverage of the global pharmaceutical market, creates a high barrier to replication.
• Switching costs: Clients embed IQVIA’s analytics and clinical workflows into their operating processes, which increases retention friction and makes displacement costly and operationally disruptive.
• Backlog and relationship depth: The $32.7 billion RDS backlog and relationships with 22 of the top 25 pharma companies suggest durable commercial stickiness, even though the filings note that many contracts may be terminable on short notice.
• Regulatory embeddedness: IQVIA’s compliance-heavy operating model and its role in decentralized trials and evidence generation reinforce its relevance in a regulated industry.

Execution Advantage

• Scale and operating leverage: With approximately 93,000 employees globally, including large TAS and RDS workforces, IQVIA can deploy capabilities at a scale that smaller peers may struggle to match.
• Margin discipline: FY 2025 showed improved SG&A efficiency, with SG&A down to 12.8% of revenue from 13.4% in the prior year, supporting profitability despite modest operating margin compression.
• Capital allocation: The company generated strong cash flow, repurchased shares, and continued active debt management, including interest savings and swap-related gains.

Overall, the moat is best characterized as moderate-to-strong, with the most defensible element being the proprietary data and analytics ecosystem. The filings support a durable competitive position, but not an impenetrable one.

Outlook & Innovation Pipeline

The source material points to a three-year outlook centered on continued scaling of data-driven healthcare intelligence, clinical trial modernization, and operational efficiency.

• RDS backlog conversion: The most visible near-term growth driver is the $32.7 billion contracted backlog, with approximately $8.1 billion expected to convert into revenue within 12 months. This provides a substantial base for medium-term revenue realization.
• Decentralized and patient-centric trials: IQVIA continues to emphasize decentralized trial capabilities and patient/site-centric solutions, indicating a strategic shift toward more flexible and modern clinical development models.
• AI-enabled analytics: The profile references proprietary Healthcare-grade AI®, suggesting ongoing investment in automation and analytics to improve delivery efficiency and margin structure.
• Commercial intelligence expansion: TAS remains a strategic growth platform, leveraging real-world evidence and granular market measurement to deepen client dependence on IQVIA’s data infrastructure.
• Customer acquisition: The addition of 400+ net new customers in RDS during 2025 indicates continued commercial momentum and potential for further penetration across the life sciences client base.

The filings do not provide a formal R&D budget or a detailed product roadmap, but they clearly indicate that IQVIA’s innovation agenda is centered on data scale, AI-enabled workflows, decentralized trials, and broader evidence-generation capabilities.